Azacitidine–venetoclax improved event-free survival in induction-eligible AML
1. In this randomized phase 2 trial involving previously untreated adults with acute myeloid leukemia, azacitidine–venetoclax improved event-free survival compared ...
Tag: induction chemotherapy
Induction chemotherapy followed by chemoradiotherapy improves survival in advanced cervical cancer
1. 5-year progression-free survival was increased in the induction chemotherapy group compared to standard chemoradiotherapy. 2. Patients in the induction ...
#VisualAbstract: Induction chemotherapy with erlotinib does not improve survival in stage III-IV head and neck squamous cell carcinoma
Click to read this study in Clinical Cancer Research.
#VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma
Click to read this study in the Journal of Clinical Oncology.
Induction chemotherapy with paclitaxel, cisplatin and capecitabine showed promising clinical and safety response to treat advanced nasopharyngeal carcinoma
1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and capecitabine group was 83.5% versus 68.9% in ...
#VisualAbstract: Capecitabine in addition to best supportive care improves progression-free survival in metastatic nasopharyngeal carcinoma
Click to read this study in JAMA Oncology.
#VisualAbstract: Induction chemotherapy does not improve survival for patients receiving chemoradiotherapy for esophageal squamous cell carcinoma
Click to read the study in Nature Communications.
#VisualAbstract: Lobaplatin-based induction chemotherapy is safe and efficacious for patients with advanced nasopharyngeal carcinomas
Click to read the study in The Lancet Oncology.
